Overview

Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment

Status:
Not yet recruiting

Trial end date:
2024-07-30

Target enrollment:

Participant gender:

Summary

A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI treatment failure ) Effectiveness of cell lung cancer patients

Phase:

N/A

Details

Lead Sponsor:

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Treatments:

Pemetrexed